Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Current place of high-dose irinotecan chemotherapy in patients with metastatic colorectal cancer.

Journal of cancer research and clinical oncology - 1 Jun 2009

Hebbar Mohamed, Ychou Marc, Ducreux Michel

Abstract excerpt

INTRODUCTION: Irinotecan has an important place in the treatment of metastatic colorectal cancer. It was initially administered as monotherapy, but is now generally used in combination with 5-fluorouracil or targeted therapies (cetuximab or bevacizumab), with various doses. METHODS: We here review the main studies assessing irinotecan doses escalation, and discuss the potent advantages of this escalation....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Phytogenic
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Camptothecin

Share to Colorectal Neoplasms

Share to Dose-Response Relationship, Drug

Share to Glucuronosyltransferase

Share to Irinotecan

Share to Neoplasm Metastasis

Source

Identifiers

PMID: 19343364
DOI: 10.1007/s00432-009-0580-x

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Current place of high-dose irinotecan chemotherapy in patients with metastatic colorectal cancer.PMID 19343364Read ↗

A phase-II study based on dose adjustment according to UGT1A1 polymorphism: is irinotecan underdosed in first-line FOLFIRI regimen for mCRC?Semantic proximity Read ↗

A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer.Semantic proximity Read ↗

Efficacy and safety of high doses of irinotecan in patients with metastatic colorectal cancer treated with the FOLFIRI regimen based on the UGT1A1 genotype: A systematic review.Semantic proximity Read ↗

Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: clinical outcome according to KRAS and BRAF mutational status.Semantic proximity Read ↗

Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer.Semantic proximity Read ↗

Irinotecan or Oxaliplatin: Which is the First Move for the Mate?Semantic proximity Read ↗

Prognostic advantage of irinotecan dose escalation according to uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping in patients with metastatic colorectal cancer treated with bevacizumab combined with 5-fluorouracil/leucovorin with irinotecan in a first-line setting.Semantic proximity Read ↗

Regorafenib plus FOLFIRI with irinotecan dose escalated according to uridine diphosphate glucuronosyltransferase 1A1 genotyping in previous treated metastatic colorectal cancer patients: study protocol for a randomized controlled trialSemantic proximity Read ↗

Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer.Semantic proximity Read ↗

High-Dose FOLFIRI plus Bevacizumab in the Treatment of Metastatic Colorectal Cancer Patients with Two Different UGT1A1 Genotypes: FFCD 0504 Study.Semantic proximity Read ↗

Irinotecan toxicity.Semantic proximity Read ↗

Gefitinib and irinotecan in patients with fluoropyrimidine-refractory, irinotecan-naive advanced colorectal cancer: a phase I-II study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.